Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

92 results about "Bromodomain" patented technology

A bromodomain is an approximately 110 amino acid protein domain that recognizes acetylated lysine residues, such as those on the N-terminal tails of histones. Bromodomains, as the "readers" of lysine acetylation, are responsible in transducing the signal carried by acetylated lysine residues and translating it into various normal or abnormal phenotypes. Their affinity is higher for regions where multiple acetylation sites exist in proximity. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. The domain itself adopts an all-α protein fold, a bundle of four alpha helices each separated by loop regions of variable lengths that form a hydrophobic pocket that recognizes the acetyl lysine.

System for controlling immune cells

The present invention relates to: a recombinant polypeptide comprising a bromodomain variant; a chimeric antigen receptor comprising the bromodomain variant in an intracellular signaling domain; a gene construct comprising a nucleotide sequence encoding the recombinant polypeptide or the chimeric antigen receptor; a cell or an immune cell, each expressing the recombinant polypeptide or the chimeric antigen receptor; a pharmaceutical composition for the prevention or treatment of cancer, comprising the immune cell; a composition for degrading the recombinant polypeptide or chimeric antigen receptor of the immune cell, the composition comprising a PROTAC compound as an active ingredient; and a kit for the prevention or treatment of cancer, comprising the pharmaceutical composition and the PROTAC compound.
Owner:KOREA RES INST OF CHEM TECH

Compound and pharmaceutical composition comprising same

PCT designated stage expiredWO2025014200A1Organic active ingredientsOrganic chemistryDiseaseBromodomain
The present invention provides: a novel compound inhibiting the activity of bromodomain, a solvate thereof, a hydrate thereof, a prodrug thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition comprising same, and is very useful for preventing and treating diseases and disorders responding to the inhibition of bromodomain-containing proteins.
Owner:TIUMBIO CO LTD

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP / p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP / p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP / p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP / p300 family of bromodomains, and methods of synthesis of these compounds.
Owner:FORMA THERAPEUTICS INC

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

The present disclosure is directed to inhibitors of the CBP / p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP / p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP / p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP / p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.
Owner:FORMA THERAPEUTICS INC

Novel histone acetyltransferase p300 bromodomain inhibitor as well as medicinal composition and application thereof

The invention discloses a p300 bromodomain inhibitor and a derivative thereof. The p300 bromodomain inhibitor has a structure as shown in a formula I: # imgabs0 #. The invention also discloses a pharmaceutical composition containing the compound and the derivative thereof and application of the pharmaceutical composition as the p300 bromodomain inhibitor. The compound and the derivative thereof can significantly inhibit the activity of histone acetyltransferase p300, have strong proliferation inhibition activity on multiple myeloma cells OPM-2, prostate cancer cells 22RV1 and the like, have good metabolic stability, safety and drug-likeness, and can be used as candidate molecules for development of antitumor drugs.
Owner:FUDAN UNIVERSITY +1

Compounds having bromodomain inhibitory activity and use thereof

Provided are compounds having bromodomain inhibitory activity and the use thereof. The compounds have structures shown as formula I. The compounds can selectively inhibit the BD2 bromodomain of the BET family, and can be used as new-generation bromodomain inhibitors for treating BET-related diseases such as cancers and inflammations.
Owner:GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

Polypeptides comprising histone cryptographic reader domains and uses thereof

The present invention relates to a polypeptide comprising a histone cipher reader domain and a use thereof, and more particularly, to a polypeptide and a use thereof in the prevention or treatment of cancer, the polypeptide comprising a PHD domain of PHF6 (PHD finger Protein 6), optionally comprising DPF3b (Double PHD finger 3b) or BPTF (Bromodomain PHD finger transcription factor), or a mutant thereof, and to a use thereof in the prevention or treatment of cancer, and more particularly, to a polypeptide comprising a PHD domain of PHF6 (PHD finger Protein 6), optionally comprising DPF3b (Double PHD finger 3b) or BPTF (Bromodomain PHD finger transcription factor), or a mutant thereof.
Owner:KOREA ADVANCED INST OF SCI & TECH +1

Crystalline form, salt form, and method for producing the same of bromodomain protein inhibitors

Crystalline and salt forms of a bromodomain protein inhibitor represented by formula (I), methods for producing the same, and use of the crystal and salt forms in the manufacture of a medicament for treating a BET protein-mediated disease. [Formula 1] TIFF2023510610000055.tif33133
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD +1

Methods for improving renal function with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

PendingNZ838491ANephrosisSodium dependent
Described herein are methods for treating and / or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.
Owner:RESVERLOGIX

Compound capable of being used as BET / p300 bromodomain double-target inhibitor as well as preparation method and application thereof

The invention relates to a compound capable of being used as a BET / p300 bromodomain double-target inhibitor or a derivative thereof as well as a preparation method and application of the compound. The compound has a structure as shown in a formula I, wherein substituent groups R1 to R4 in the formula # imgabs0 are defined in the specification. The invention also relates to a pharmaceutical composition containing the compound or the derivative thereof, application of the compound or the derivative thereof as a BET / p300 bromodomain double-target inhibitor, and a preparation method of the compound or the derivative thereof. The compound or the derivative thereof can significantly inhibit the activity of BET / p300 bromodomain, has a significant anti-proliferation effect on cancer cells and multiple myeloma cells, and also has good metabolic stability, safety and drug-likeness, so that the compound or the derivative thereof has a wide application prospect.
Owner:FUDAN UNIVERSITY +2

Covalent tag

The present disclosure concerns a compound of formula (I) and / or a tagged compound of formula (IA), each of which are capable of binding to a complementary hole-modified mutant bromodomain, also presented herein. The disclosure also concerns the use of the compounds in various applications, a method of covalently binding a target biomolecule with a compound or tagged compound, and a kit comprising: a compound or tagged compound, and a construct comprising a nucleic acid encoding a complementary hole-modified mutant bromodomain.
Owner:UNIVERSITY OF DUNDEE +1

Application of a bromodomain protein 4 active compound based on a water network strategy

The present invention discloses an application of a bromodomain protein 4 active compound based on a water network strategy. The bromodomain protein 4 active compound can be used to prepare a drug that inhibits the activity of bromodomain protein 4, and can be used to prepare a pharmaceutically acceptable salt. In addition, the bromodomain protein 4 active compound and the pharmaceutically acceptable salt prepared therefrom can also be used to prepare a bromodomain protein 4 inhibitor and the pharmaceutically acceptable salt prepared therefrom, as well as a pharmaceutical composition for preparing a prostate cancer cell proliferation inhibitor, an anti-prostate tumor drug, and a pharmaceutical composition for treating bromodomain protein 4-related diseases. The bromodomain protein 4 inhibitor prepared based on the bromodomain protein 4 active compound having obvious inhibitory activity of the present invention is applied to the treatment of diseases related to bromodomain protein 4, has high reliability, is easy to promote and popularize, and utilizes the potential advantages of the bromodomain protein 4 active compound as a drug or pharmaceutical composition, opening up a new approach for the treatment of related diseases.
Owner:ZHEJIANG UNIV

In SITU tumor vaccine to promote Anti-tumor immunity

Provided herein are methods and compositions for treating cancer by administering an in-situ cancer vaccine, such as comprising tumor directed radiation therapy and a Bromodomain and Extra-Terminal motif (BET) inhibitor.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Application of super enhancer inhibitor JQ-1 in wound healing disorder related diseases

The invention provides application of a super enhancer inhibitor JQ-1 in preparation of a medicine for treating wound healing disorder related diseases. Relates to the technical field of biomedicine, the promotion effect of the super enhancer inhibitor JQ-1 in wound healing and repairing is disclosed for the first time, the super enhancer inhibitor JQ-1 is competitively combined with BET protein bromodomain, combination of the super enhancer inhibitor JQ-1 and acetylated histone is blocked, and super enhancer driven gene transcription is inhibited. Skin regeneration can be obviously accelerated, the wound healing time is shortened, and the healing degree is improved. Aiming at the pain point that the existing wound healing therapy is limited in effect, the invention provides a brand-new molecular targeted therapy scheme for people, such as diabetic patients and old people, which are easy to cause abnormal wound healing, can effectively reduce serious sequelae, such as amputation, and provides a scientific basis and a key direction for developing a novel medicine for promoting wound healing; the technical blank in the related treatment field is filled up, and important clinical application value and research and development prospects are achieved.
Owner:NANTONG UNIV

Compounds and methods for the targeted degradation of bromodomain-containing proteins

PendingUS20250228944A1Protein targetBromodomain
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and / or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation / inhibition of targeted polypeptides.
Owner:ARVINAS OPERATIONS INC +1

Extended and delayed release compositions of substituted benzimidazoles

PCT designated stage expiredWO2024249796A2Organic active ingredientsDrageesDiseaseBromodomain
Provided herein are substituted benzimidazole compounds that may be useful for inhibition of bromodomains, pharmaceutical compositions comprising said compounds, extended and delayed release compositions, and methods of treating diseases and conditions with said compositions.
Owner:EPIGENETIX INC

Indolizine compound and use thereof

PCT designated stageWO2026145825A1BromodomainCombinatorial chemistry
Provided in the present invention is an indolizine compound having a structure as represented by formula I, formula II, or formula III. The indolizine compound provided in the present invention can effectively bind to a BRD7 / BRD9 bromodomain, and has a good effect. Moreover, the indolizine compound provided in the present invention has a stable structure and a simpler synthesis method.
Owner:GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

ActiveUS12673059B2DiseaseSodium dependent
Described herein are methods for treating and / or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.
Owner:RESVERLOGIX

Inhibition of BRD proteins suppresses the phenotype of uterine fibroids

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain (BRD) protein.
Owner:UNIVERSITY OF CHICAGO

Method of manufacturing a solid form of a BET bromodomain inhibitor

The invention relates to solid crystalline forms of Compound (I), such as e.g., Form VII, including pharmaceutical compositions thereof and processes for preparing crystalline Compound (I), Form VII. Compound (I) modulates or inhibits the activity of BET bromodomain-containing proteins, and is useful in the treatment of diseases such as cancer, inflammatory and cardiovascular diseases.
Owner:ZENITH EPIGENETICS LTD

Method of manufacturing solid form of bet bromodomain inhibitor

To provide solid crystalline forms of a compound that modulates or inhibits the activity of BET bromodomain-containing proteins.SOLUTION: Provided is a form of Compound I which: (a) when measured on a diffractometer using a Cu-Kα radiation source, has three or more characteristic XRPD peaks at 2θ of 7.2, 10.3, 11.2, 12.0, 13.8, 13.9, 15.2, 15.6, 16.5, 17.3, 20.7, 20.9, 21.6, and 22.5°, wherein each peak is at ±0.2°θ; or (b) when measured on a diffractometer using a Cu-Kα radiation source, has six or more characteristic XRPD peaks at 2θ of 7.2, 10.3, 11.2, 12.0, 13.8, 13.9, 15.2, 15.6, 16.5, 17.3, 20.7, 20.9, 21.6, and 22.5°, wherein each peak is at ±0.2°θ.SELECTED DRAWING: None
Owner:ZENITH EPIGENETICS LTD

Method of manufacturing a solid form of a bet bromodomain inhibitor

The invention relates to solid crystalline forms of Compound (I), such as e.g., Form VII, including pharmaceutical compositions thereof and processes for preparing crystalline Compound (I), Form VII. Compound (I) modulates or inhibits the activity of BET bromodomain-containing proteins, and is useful in the treatment of diseases such as cancer, inflammatory and cardiovascular diseases.
Owner:ZENITH EPIGENETICS LTD